Literature DB >> 23454274

Protein kinase C delta is a substrate of tissue transglutaminase and a novel autoantigen in coeliac disease.

Greg Byrne1, Michael Freeley2, Con Feighery3, Alex Whelan3, Aideen Long2.   

Abstract

Post-translational modification of proteins by deamidation or transamidation by tissue transglutaminase (tTG) has been suggested as a possible mechanism for the development of autoimmunity. Sequence analysis of protein kinase C delta (PKCδ) identified an amino acid motif that suggested the possibility that PKCδ was a glutamine substrate of tTG and MALDI-TOF analysis of synthesised peptides from PKCδ proved that this was the case. Polymerisation experiments using recombinant tTG and biotinylated hexapeptide substrate incorporation assays demonstrated that PKCδ is a substrate for tTG-mediated transamidation. Elevated levels of anti-PKCδ antibodies were detected in sera from patients with coeliac disease (p<0.0001) but not from patients with other autoimmune disorders. These data suggest that a subset of patients with coeliac disease produce autoantibodies against PKCδ and that this response may stem from a tTG-PKCδ substrate interaction.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23454274     DOI: 10.1016/j.clim.2013.01.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  2 in total

1.  CGX1037 is a novel PKC isoform delta selective inhibitor in platelets.

Authors:  Dheeraj Bhavanasi; John C Kostyak; John Swindle; Laurie E Kilpatrick; Satya P Kunapuli
Journal:  Platelets       Date:  2014-01-16       Impact factor: 3.862

2.  Shared Genetic Factors Involved in Celiac Disease, Type 2 Diabetes and Anorexia Nervosa Suggest Common Molecular Pathways for Chronic Diseases.

Authors:  Joanna Mostowy; Caroline Montén; Audur H Gudjonsdottir; Henrik Arnell; Lars Browaldh; Staffan Nilsson; Daniel Agardh; Åsa Torinsson Naluai
Journal:  PLoS One       Date:  2016-08-02       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.